# Jason S. Lewis

Source: https://onco.cc/people/jason-lewis/  
OnCo record `jason-lewis` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.

## Summary

Jason Lewis developed methods for labelling antibodies with zirconium-89 that made immuno-PET a clinical reality, including 89Zr-trastuzumab and 89Zr-J591 PSMA imaging, and leads a laboratory translating new radiotracers and radioligand therapies from chemistry to first-in-human trials. He directs radiochemistry at MSKCC and has trained many of the field's leaders.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: radiochemistry; immuno-pet; theranostics
- Role: Emily Tow Jackson Chair in Oncology and Chief Attending, Radiochemistry and Imaging Sciences Service, Memorial Sloan Kettering Cancer Center
- Specialisms: Radiochemistry; Immuno-PET; Radiopharmaceutical development; Targeted radiotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET

## Connected records

- technologies: [HER2 PET](https://onco.cc/technologies/her2-pet/), [Immuno-PET](https://onco.cc/technologies/immuno-pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [HER2](https://onco.cc/targets/her2/), [PSMA](https://onco.cc/targets/psma/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- journals: [Journal of Nuclear Medicine](https://onco.cc/journals/journal-of-nuclear-medicine/)

---
JSON: https://onco.cc/api/v1/entities/jason-lewis.json